US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...
FDA approves at-home flu vaccine
The FDA is clearing the way for an at-home flu vaccines. A self-administered version of pharmaceutical giant AstraZeneca’s ...
STAT1d
FDA approves first at-home flu vaccine in U.S., a nasal spray
FluMist is the only flu vaccine administered by nasal spray, not injection. It is licensed for individuals between the ages ...
KELO1d
US FDA approves AstraZeneca’s flu vaccine for self-administration
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
The greatest British shares to invest in: Their steady and dependable growth is a testament to the power of UK plc
Americans love their Star-Spangled Banner, the French are obsessed with national pride but we Brits have a patriotism problem ...
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the ...
Investor ideas4d
Cancer's Solid Tumors Market - the Stocks to Watch
According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...
Medscape5d
Will New Obesity Drugs Make Bariatric Surgery Obsolete?
Aronne, MD, of Weill Cornell Medicine in New York City, made a compelling case that the next generation of obesity ...
FierceBiotech8d
ESMO: AstraZeneca steps out from Daiichi's shadow, posting data on ADC rivals to AbbVie, Pfizer
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
FiercePharma8d
ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value from new cancer meds
Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...